TriSalus Life Sciences’ Pressure Enabled Drug Delivery (PEDD) method enhances the delivery of glass microspheres into liver tumors in a porcine model. Published in the Journal of Vascular and Interventional Radiology, the study demonstrates that PEDD significantly improves penetration of glass microspheres into tumors using the TriNav Infusion System.
Compared to conventional microcatheters, the PEDD method showcased deeper penetration of glass microspheres into liver tumors and surrounding tissue. This advanced delivery method offers the potential for increased therapeutic efficacy and reduced side effects.
Bryan F. Cox, TriSalus’ Chief of Research, emphasizes the significance of PEDD in addressing challenges in cancer care. The enhanced delivery observed in the study validates the method’s ability to target tumors with therapeutics selectively.
Mary Szela, TriSalus’ CEO, highlights the practical implications of PEDD. The efficient delivery of therapeutics to tumor cells without affecting healthy tissue remains a challenge in cancer treatment, and PEDD aims to overcome this barrier.
The study findings suggest that the PEDD method improves glass microsphere delivery regardless of its placement (lobar or selective infusions). The TriNav device enables controlled and targeted delivery of glass microspheres and other drugs into tumors.
Dr. Riad Salem, Chief of Interventional Radiology, emphasizes the potential of PEDD in addressing unmet needs in liver cancer therapy. The increased concentration of microspheres in tumors compared to surrounding liver tissue suggests improved efficacy and safety. Further validation in human models could lead to significant advancements in liver cancer management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
